Evommune Initiates Phase 1 Study to Evaluate Safety of EVO101, an IRAK4 Inhibitor, in Healthy Volunteers
Marks key milestone as Evommune's first clinical program which should allow EVO101 to rapidly advance into Phase 2a
Plexium Announces $102M Financing To Advance Pipeline Of Targeted Protein Degradation Therapies And Technology Platform
SAN DIEGO, Feb. 23, 2022 /PRNewswire/ -- Plexium, Inc. (Plexium), a leading next-generation targeted protein degradation (TPD) company, today announced the completion of an oversubscribed $102M financing, led by BVF…
- Go to the previous page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- …
- 82
- Go to the next page
